304 related articles for article (PubMed ID: 21261567)
1. Antibody-based therapy in Alzheimer's disease.
Pul R; Dodel R; Stangel M
Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y; Liu Y; Wang Z; Jiang Y
Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
[TBL] [Abstract][Full Text] [Related]
5. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy as treatment for Alzheimer's disease.
Hawkes CA; McLaurin J
Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
[TBL] [Abstract][Full Text] [Related]
7. Engineered antibody approaches for Alzheimer's disease immunotherapy.
Robert R; Wark KL
Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
Cedernaes J; Schiöth HB; Benedict C
Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
[TBL] [Abstract][Full Text] [Related]
9. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
Murakami K
Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
[TBL] [Abstract][Full Text] [Related]
10. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T; Boutajangout A
Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
[TBL] [Abstract][Full Text] [Related]
12. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
13. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
Schenk DB; Seubert P; Grundman M; Black R
Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
[TBL] [Abstract][Full Text] [Related]
14. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
Morgan D; Gitter BD
Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
[TBL] [Abstract][Full Text] [Related]
15. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic approaches for Alzheimer's disease.
Wisniewski T; Goñi F
Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
[TBL] [Abstract][Full Text] [Related]
17. Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.
Hutton M; McGowan E
Neuron; 2004 Aug; 43(3):293-4. PubMed ID: 15294135
[TBL] [Abstract][Full Text] [Related]
18. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
19. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
Kayed R; Jackson GR
Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
[TBL] [Abstract][Full Text] [Related]
20. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]